Drug Approval | December 03, 2021
Biocon Pharma receives ANDA approval for Mycophenolic acid
This further adds to Biocon’s portfolio of vertically integrated complex drug products
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Subscribe To Our Newsletter & Stay Updated
